Market Overview

UPDATE: Piper Jaffray Initiates Geron Corporation at Overweight on Risk/Reward

Share:
Related GERN
Oppenheimer Is Excited About These 3 Biotech Stocks
Benzinga's Top #PreMarket Gainers
Trio Of Small Biotechs With Upcoming 2015 Catalysts And Enormous Long-Term Potential (Seeking Alpha)

Piper Jaffray initiated coverage on Geron Corporation (NASDAQ: GERN) with a Overweight rating and a $3.00 price target.

Piper Jaffray commented, "Geron is focused on developing drugs from its novel telomerase-inhibitor platform and its 1st-in-class compound imetelstat is targeting hematological indications. The mechanistic logic behind the use of imetelstat to treat hematological malignancies is sound, in our view, and is supported by early clinical evidence in this setting, most recently presented at ASH '12. We view the current valuation of GERN shares as pricing in the past programmatic challenges and thus limiting downside, with substantial upside potential as more data and visibility of clinical progress emerges over the course of 2013/1H14."

Geron Corporation closed at $1.64 on Thursday.

Latest Ratings for GERN

DateFirmActionFromTo
Apr 2015OppenheimerInitiates Coverage onOutperform
Jun 2014MLV & Co.UpgradesHoldBuy
Mar 2014NeedhamDowngradesBuyHold

View More Analyst Ratings for GERN
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (GERN)

Around the Web, We're Loving...

Get Benzinga's Newsletters